|
LOBBYING REPORT |
Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page
2. Address
| Address1 | 1201 Maryland Avenue SW |
Address2 | Suite 900 |
| City | Washington |
State | DC |
Zip Code | 20024 |
Country | USA |
3. Principal place of business (if different than line 2)
| City |
|
State |
|
Zip Code |
|
Country |
|
|
5. Senate ID# 6245-12
|
||||||||
|
6. House ID# 325050000
|
||||||||
| TYPE OF REPORT | 8. Year | 2018 |
Q1 (1/1 - 3/31) | Q2 (4/1 - 6/30) | Q3 (7/1 - 9/30) | Q4 (10/1 - 12/31) |
9. Check if this filing amends a previously filed version of this report
| 10. Check if this is a Termination Report | Termination Date |
|
11. No Lobbying Issue Activity |
| INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13 | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| 12. Lobbying | 13. Organizations | ||||||||
| INCOME relating to lobbying activities for this reporting period was: | EXPENSE relating to lobbying activities for this reporting period were: | ||||||||
|
|
||||||||
|
|
||||||||
| Provide a good faith estimate, rounded to the nearest $10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). | 14. REPORTING Check box to indicate expense accounting method. See instructions for description of options. | ||||||||
|
Method A.
Reporting amounts using LDA definitions only
Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code Method C. Reporting amounts under section 162(e) of the Internal Revenue Code |
|||||||||
| Signature | Digitally Signed By: Tom DiLenge |
Date | 4/20/2018 4:45:42 PM |
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code AGR
16. Specific lobbying issues
Agricultural Education Policy
Biomass Programs (Non-Funding)
---Farm Bill Reauthorization
---Reauthorization of Biomass Crop Assistance Program
---Reauthorization of Biomass R&D Program
EPA Regulations on Biotechnology
---H.R. 1029 Pesticide Registration Act
Foreign Agricultural Biotechnology Laws and Regulations
---Asynchronous Approvals
---China Biotechnology Regulations
---EU Ag-Biotech Policies and Regulations
---Like-minded countries initiatives
Funding for Biomass Crop Assistance Program
---Farm Bill Reauthorization
---H.R. 3268/S.1603: Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2018
Funding for the USDA
---H.R. 3268/S.1603: Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2018
---Foreign Agriculture Service Funding and Authority
------H.R. 5379: Growing American Food Exports Act
Genetically Engineered (GE) Animals
---Labeling
---Efficient Science-Based Review of Biotech Products
---FDA Proposed Guidance on Gene Editing
---H.R. 3268/S.1603: Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2018
------Amendment on GE Salmon Labeling
North American Free Trade Agreement (NAFTA) Renegotiation
---Ag-Biotech Provisions
One Health
---S. 2615: Advancing Emergency Preparedness Through One Health Act
Potential Regulation of New Genetic Modification Technologies
Review and Labeling of Food Derived from Biotechnology
---Implementation of Disclosure Law
USDA/APHIS Agricultural Biotechnology Regulations
---Efficient Science-Based Review of Biotech Products
---Farm Bill Reauthorization
---Potential Revisions to Part 340 Regulations
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Agriculture - Dept of (USDA), Food & Drug Administration (FDA), U.S. Trade Representative (USTR), White House Office, Natl Economic Council (NEC), Natl Security Council (NSC)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Dana |
OBrien |
|
|
|
Erick |
Lutt |
|
|
|
Hayley |
Alexander |
|
|
|
Jeanne |
Haggerty |
|
|
|
Kyle |
Kunkler |
|
|
|
Matthew |
OMara |
|
|
|
Rina |
Singh |
|
|
|
Sarah |
Kyle |
|
|
|
Dan |
Jenkins |
|
|
|
Jordan |
Bartolomeo |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code ANI
16. Specific lobbying issues
Genetically Engineered (GE) Animals
---Labeling
---Efficient Science-Based Review of Biotech Products
---FDA Proposed Guidance on Gene Editing
---H.R. 3268/S.1603: Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2018
------Amendment on GE Salmon Labeling
One Health
---S. 2615: Advancing Emergency Preparedness Through One Health Act
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Agriculture - Dept of (USDA), Food & Drug Administration (FDA), White House Office, Natl Economic Council (NEC)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Hayley |
Alexander |
|
|
|
Jeanne |
Haggerty |
|
|
|
Kyle |
Kunkler |
|
|
|
Dana |
O'Brien |
|
|
|
Jordan |
Bartolomeo |
|
|
|
Dan |
Jenkins |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code BUD
16. Specific lobbying issues
Energy Basic Research Funding
---Advanced Research Projects Agency-Energy
---H.R.3266: Energy and Water Development and Related Agencies Appropriations Act for FY 2018
Funding for Antimicrobial Resistance Programs
---H.R. 3268/S.1603: Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2018
---H.R. 3358/S.1771: Departments of Labor, HHS, Education, and Related Agencies Appropriations Act for FY 2018
Funding for Biodefense/Biomedical/Emergency Preparedness Research, Development and Procurement
---H.R. 3358/S.1771: Departments of Labor, HHS, Education, and Related Agencies Appropriations Act for FY 2018
Funding for Biofuels
---Farm Bill Reauthorization
---H.R. 3266/S.1609: Energy and Water Development and Related Agencies Appropriations Act for FY 2018
---H.R. 3268/S.1603: Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2018
Funding for Biomass Crop Assistance Program
---Farm Bill Reauthorization
---H.R. 3268/S.1603: Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2018
Funding for Biorefineries
---Farm Bill Reauthorization
---Reauthorization of Biorefinery, Renewable Chemical, and Biobased Product Manufacturing Assistance Program
---H.R. 3268/S.1603: Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2018
Funding for FDA
---H.R. 3268/S.1603: Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2018
Funding for National Institutes of Health
---H.R. 3358/S.1771: Departments of Labor, HHS, Education, and Related Agencies Appropriations Act for FY 2018
Funding for Renewable Chemicals/Bio-based Products
---Farm Bill Reauthorization
---Reauthorization of Biorefinery, Renewable Chemical, and Biobased Product Manufacturing Assistance Program
---Reauthorization of USDA Bio-Preferred Program
---H.R. 3268/S.1603: Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2018
Funding for the Centers for Disease Control and Prevention Vaccine Programs
---H.R. 3358/S.1771: Departments of Labor, HHS, Education, and Related Agencies Appropriations Act for FY 2018
Funding for the USDA
---H.R. 3268/S.1603: Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2018
---Foreign Agriculture Service Funding and Authority
------H.R. 5379: Growing American Food Exports Act
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Agriculture - Dept of (USDA), Food & Drug Administration (FDA)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Erick |
Lutt |
|
|
|
Hayley |
Alexander |
|
|
|
Jeanne |
Haggerty |
|
|
|
Jordan |
Bartolomeo |
|
|
|
Kyle |
Kunkler |
|
|
|
Phi D. |
Vu |
|
|
|
Phyllis |
Arthur |
|
|
|
Rina |
Singh |
|
|
|
Sarah |
Kyle |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code CHM
16. Specific lobbying issues
Funding for Renewable Chemicals/Bio-based Products
---Farm Bill Reauthorization
---Reauthorization of Biorefinery, Renewable Chemical, and Biobased Product Manufacturing Assistance Program
---Reauthorization of USDA Bio-Preferred Program
---H.R. 3268/S.1603: Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2018
Renewable Chemicals/Bio-based Products (Non-Funding)
---Expansion of Master Limited Partnerships to Renewable Chemicals
---Investment Tax Credit
---Production Tax Credit
---Reauthorization of Biorefinery, Renewable Chemical, and Biobased Product Manufacturing Assistance Program
---Reauthorization of USDA Bio-Preferred Program
---Nomenclature Usage
---Farm Bill Reauthorization
---H.R. 3149/S.1980: Renewable Chemicals Act of 2017
---H.R. 4118/S.2005: Master Limited Partnership Parity Act
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Agriculture - Dept of (USDA)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Charles |
Fritts |
|
|
|
Erick |
Lutt |
|
|
|
Hayley |
Alexander |
|
|
|
Jeanne |
Haggerty |
|
|
|
Kyle |
Kunkler |
|
|
|
Rina |
Singh |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code CPT
16. Specific lobbying issues
Bayh-Dole Act/Tech Transfer
---March-In Rights
Intellectual Property International Enforcement
---Compulsory Licensing
---World Trade Organization - Special 301 Submission
---India
---Canada
---Malaysia
Inter Partes Review
---Implementation of the America Invents Act of 2011
---H.R. 5340/S. 1390: STRONGER Patents Act
---Biomedical Innovation Protection Act of 2018 (Discussion Draft House/Senate)
International IP Patent Law Harmonization
North American Free Trade Agreement (NAFTA) Renegotiation
---IP Provisions
Patent Reform
---H.R. 5340/S. 1390: STRONGER Patents Act
Small Business Intellectual Property Training
---H.R. 2655: Small Business Innovation Protection Act
UN High Level Commission on Access to Medicines
---IP Proposals
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, U.S. Trade Representative (USTR), White House Office
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Charles |
Fritts |
|
|
|
David |
Lachmann |
|
|
|
Hans |
Sauer |
|
|
|
Jeanne |
Haggerty |
|
|
|
Joseph |
Damond |
|
|
|
Melissa |
Brand |
|
|
|
Sarah |
Kyle |
|
|
|
Matthew |
OMara |
|
|
|
Jordan |
Bartolomeo |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code CSP
16. Specific lobbying issues
Drug Importation
---S. 771: Improving Access to Affordable Prescription Drugs
---S.469: Affordable and Safe Prescription Drug Importation Act
---H.R. 3268/S.1603: Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2018
---H.R. 3358/S.1771: Departments of Labor, HHS, Education, and Related Agencies Appropriations Act for FY 2018
Genetically Engineered (GE) Animals
---Labeling
---Efficient Science-Based Review of Biotech Products
---FDA Proposed Guidance on Gene Editing
---H.R. 3268/S.1603: Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2018
------Amendment on GE Salmon Labeling
Opioid Crisis
---NIH Research
---FDA Reforms
---Coverage and Reimbursement
---Discussion Drafts House/Senate
Review and Labeling of Food Derived from Biotechnology
---Implementation of Disclosure Law
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Agriculture - Dept of (USDA), Food & Drug Administration (FDA), Natl Institutes of Health (NIH), White House Office, Natl Economic Council (NEC)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Cartier |
Esham |
|
|
|
Dana |
OBrien |
|
|
|
Hayley |
Alexander |
|
|
|
Jamie |
Gregorian |
|
|
|
Jeanne |
Haggerty |
|
|
|
Jordan |
Bartolomeo |
|
|
|
Kyle |
Kunkler |
|
|
|
Sarah |
Kyle |
|
|
|
Taylor |
Booth |
|
|
|
Dan |
Jenkins |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code ENG
16. Specific lobbying issues
Biofuels (Non-Funding)
---Accelerated Depreciation of Biofuels Facilities Extension
---Farm Bill Reauthorization
---Production Tax Credit Extension
---Reauthorization of Biorefinery, Renewable Chemical, and Biobased Product Manufacturing Assistance Program
---H.R. 4118/S. 2005: Master Limited Partnership Parity Act
---H.R. 1892: Bipartisan Budget Act of 2018
Biomass Programs (Non-Funding)
---Farm Bill Reauthorization
---Reauthorization of Biomass Crop Assistance Program
---Reauthorization of Biomass R&D Program
Biorefineries (non-funding)
---Reauthorization of Biorefinery, Renewable Chemical, and Biobased Product Manufacturing Assistance Program
Energy Basic Research Funding
---Advanced Research Projects Agency-Energy
---H.R. 3266: Energy and Water Development and Related Agencies Appropriations Act for FY 2018
Funding for Biofuels
---Farm Bill Reauthorization
---H.R. 3266/S.1609: Energy and Water Development and Related Agencies Appropriations Act for FY 2018
---H.R. 3268/S.1603: Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2018
Funding for Biomass Crop Assistance Program
---Farm Bill Reauthorization
---H.R. 3268/S.1603: Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2018
Funding for Biorefineries
---Farm Bill Reauthorization
---Reauthorization of Biorefinery, Renewable Chemical, and Biobased Product Manufacturing Assistance Program
---H.R. 3268/S.1603: Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2018
Renewable Fuel Standard (RFS)
---Changes to the Point of Obligation under the RFS
---RFS Reform
---H.R. 1311/S.517: Consumer and Fuel Retailer Choice Act
Review of the Federal Coordinated Framework for Biotechnology Products
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Agriculture - Dept of (USDA), Environmental Protection Agency (EPA)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Charles |
Fritts |
|
|
|
Erick |
Lutt |
|
|
|
Hayley |
Alexander |
|
|
|
Jeanne |
Haggerty |
|
|
|
Kyle |
Kunkler |
|
|
|
Rina |
Singh |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code FOO
16. Specific lobbying issues
Genetically Engineered (GE) Animals
---Labeling
---Efficient Science-Based Review of Biotech Products
---FDA Proposed Guidance on Gene Editing
---H.R. 3268/S.1603: Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2018
--------Amendment on GE Salmon Labeling
Review and Labeling of Food Derived from Biotechnology
---Implementation of Disclosure Law
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Agriculture - Dept of (USDA), Food & Drug Administration (FDA), White House Office, Natl Economic Council (NEC)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Dana |
OBrien |
|
|
|
Hayley |
Alexander |
|
|
|
Jeanne |
Haggerty |
|
|
|
Kyle |
Kunkler |
|
|
|
Jordan |
Bartolomeo |
|
|
|
Dan |
Jenkins |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code FUE
16. Specific lobbying issues
Biofuels (Non-Funding)
---Accelerated Depreciation of Biofuels Facilities Extension
---Farm Bill Reauthorization
---Production Tax Credit Extension
---Reauthorization of Biorefinery, Renewable Chemical, and Biobased Product Manufacturing Assistance Program
---H.R. 4118/S. 2005: Master Limited Partnership Parity Act
---H.R. 1892: Bipartisan Budget Act of 2018
Biomass Programs (Non-Funding)
---Farm Bill Reauthorization
---Reauthorization of Biomass Crop Assistance Program
---Reauthorization of Biomass R&D Program
Biorefineries (non-funding)
---Reauthorization of Biorefinery, Renewable Chemical, and Biobased Product Manufacturing Assistance Program
Energy Basic Research Funding
---Advanced Research Projects Agency-Energy
---H.R. 3266: Energy and Water Development and Related Agencies Appropriations Act for FY 2018
Funding for Biofuels
---Farm Bill Reauthorization
---H.R. 3266/S.1609: Energy and Water Development and Related Agencies Appropriations Act for FY 2018
---H.R. 3268/S.1603: Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2018
Funding for Biomass Crop Assistance Program
---Farm Bill Reauthorization
---H.R. 3268/S.1603: Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2018
Funding for Biorefineries
---Farm Bill Reauthorization
---Reauthorization of Biorefinery, Renewable Chemical, and Biobased Product Manufacturing Assistance Program
---H.R. 3268/S.1603: Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2018
Renewable Fuel Standard (RFS)
---Changes to the Point of Obligation under the RFS
---RFS Reform
---H.R. 1311/S.517: Consumer and Fuel Retailer Choice Act
Review of the Federal Coordinated Framework for Biotechnology Products
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Agriculture - Dept of (USDA), Environmental Protection Agency (EPA)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Charles |
Fritts |
|
|
|
Erick |
Lutt |
|
|
|
Hayley |
Alexander |
|
|
|
Jeanne |
Haggerty |
|
|
|
Kyle |
Kunkler |
|
|
|
Rina |
Singh |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code HCR
16. Specific lobbying issues
340B Drug Discount Program
---Program Implementation & Oversight
---H.R. 3358/S.1771: Departments of Labor, HHS, Education, and Related Agencies Appropriations Act for FY 2018
---H.R. 4710: 340B Pause Act
---S. 2453: Ensuring the Value of the 340B Program Act
Access to Medicines/World Health Organization
Antibiotic & Diagnostic Tax Credit
---H.R. 1840: Reinvigorating Antibiotic and Diagnostic Innovation
Biodefense Research, Development and Procurement Issues (Non-funding)
---Tropical Disease Priority Review Voucher (PRV) Program
---Implementation of Medical Countermeasures Innovation Act
---H.R. 3358/S.1771: Departments of Labor, HHS, Education, and Related Agencies Appropriations Act for FY 2018
---Pandemic and All-Hazards Preparedness Act (PAHPA) Reauthorization Act of 2017 (Reps. Brooks/Eshoo Discussion Draft)
Biosimilars
---S. 974/H.R. 2212: CREATES Act of 2017
---Access to Samples for Testing
---Columbia Biologics Regulation
---Coding
---H.R. 1892: Bipartisan Budget Act of 2018
---H.R. 1625: Consolidated Appropriations Act for FY 2018
Drug Evaluation and Review
---Compassionate Use/Expanded Access
---Expedited Pathways
---FDA Proposed Rule on Changes to Drug Labeling
---Innovation Incentives
---Patient-Focused Drug Development
---S.204 / H.R. 878: Right to Try Act of 2017
---Prescription Drug User Fee Act (PDUFA) VI Implementation
---Biosimilar User Fee Amendments (BSUFA) II Implementation
---FDA Hiring Flexibility
---Priority Review Voucher Program
---Regulatory Reform & Modernization
---Use of Real World Evidence
Drug Importation
---H.R. 3268/S.1603: Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2018
---H.R. 3358/S.1771: Departments of Labor, HHS, Education, and Related Agencies Appropriations Act for FY 2018
---S. 771: Improving Access to Affordable Prescription Drugs
---S.469: Affordable and Safe Prescription Drug Importation Act
Drug Manufacturing, Quality & Distribution
---Pharmacy Compounding & Oversight
---Drug Shortages
---Supply Chain Integrity and Traceability
---H.R. 2871: Preserving Patient Access to Compound Medications
Drug Pricing
---S. 1348: Stopping the Pharmaceutical Industry from Keeping Drugs Expensive (SPIKE) Act of 2017
---S. 1369 / H.R. 2974: Stop Price Gouging Act
---S. 637: Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act
---S. 771: Improving Access to Affordable Prescription Drugs
Drug Product Communications
---H.R. 1703: The Medical Products Communications Act
---H.R. 2026: Pharmaceutical Information Exchange Act
Foreign Drug Data Protection Laws
Funding for Antimicrobial Resistance Programs
---H.R. 3268/S.1603: Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2018
---H.R. 3358/S.1771: Departments of Labor, HHS, Education, and Related Agencies Appropriations Act for FY 2018
Funding for Biodefense/Biomedical/Emergency Preparedness Research, Development and Procurement
---H.R. 3219: Department of Defense Appropriations Act for FY 2018
---H.R. 3358/S.1771: Departments of Labor, HHS, Education, and Related Agencies Appropriations Act for FY 2018
Funding for FDA
---H.R. 3268/S.1603: Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2018
Funding for National Institutes of Health
---H.R. 3358/S.1771: Departments of Labor, HHS, Education, and Related Agencies Appropriations Act for FY 2018
Funding for the Centers for Disease Control and Prevention Vaccine Programs
---H.R. 3358/S.1771: Departments of Labor, HHS, Education, and Related Agencies Appropriations Act for FY 2018
Generic Drug Entry
---Access to Samples for Testing
---Generic Drug Application Review Reforms
---Incentives for Generic Entry
---H.R. 297: Increasing Competition in Pharmaceuticals Act
---H.R. 749: Lower Drug Costs through Competition Act
---S. 974/H.R. 2212: CREATES Act of 2017
---H.R. 1892: Bipartisan Budget Act of 2018
---H.R. 1625: Consolidated Appropriations Act for FY 2018
Independent Payment Advisory Board Repeal
---H.R. 849/S. 260: Protecting Seniors' Access to Medicare Act
---H.R. 1892: Bipartisan Budget Act of 2018
---H.R. 1625: Consolidated Appropriations Act for FY 2018
International Biosecurity Policies
Medicaid
---Drug Benefit Design
---Pricing and Rebates
---Average Manufacturer Price Calculations
North American Free Trade Agreement (NAFTA) Renegotiation
---Pricing and Reimbursement Provisions
---IP Provisions
Opioid Crisis
---NIH Research
---FDA Reforms
---Coverage and Reimbursement
---Discussion Drafts House/Senate
Orphan Drug Issues
---Technical Amendments
---Tax Credit
Reimbursement for Innovative Products
---Medicare Part B Physician-Administered Products
---Medicare Part D Prescription Drug Program
---S. 771: Improving Access to Affordable Prescription Drugs
---Third Party Support of Patient Premiums and Cost-Sharing Obligations
---Value-based Contracting and Communications
---CMS Hospital Inpatient Proposed Rule
---S. 1688: Empowering Medicare Seniors to Negotiate Drug Prices Act of 2017
---H.R. 242: Medicare Prescription Drug Price Negotiation Act
---H.R. 4138: Medicare Drug Price Negotiation Act
---H.R. 1892: Bipartisan Budget Act of 2018
---H.R. 1625: Consolidated Appropriations Act for FY 2018
Trade and Foreign Drug Price Controls
UN High Level Commission on Access to Medicines
---IP Proposals
Vaccines and Infectious Diseases
---Vaccine and Anti-Microbial Resistance Product Development and Incentives
---Vaccine Injury Compensation Program
---Vaccine Safety
---Adult Immunization Education
---H.R. 4993: Vaccine Access Improvement Act
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), Health Resources & Services Administration (HRSA), Natl Institutes of Health (NIH), Natl Security Council (NSC), White House Office, U.S. Trade Representative (USTR), Natl Economic Council (NEC), Office of Management & Budget (OMB)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Cartier |
Esham |
|
|
|
Charles |
Fritts |
|
|
|
David |
Lachmann |
|
|
|
Hayley |
Alexander |
|
|
|
Jamie |
Gregorian |
|
|
|
Jeanne |
Haggerty |
|
|
|
Jordan |
Bartolomeo |
|
|
|
Joseph |
Damond |
|
|
|
Phi D. |
Vu |
|
|
|
Phyllis |
Arthur |
|
|
|
Sarah |
Kyle |
|
|
|
Taylor |
Booth |
|
|
|
John |
Murphy |
|
|
|
Cameron |
Arterton |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code HOM
16. Specific lobbying issues
Biodefense Research, Development and Procurement Issues (Non-funding)
---Tropical Disease Priority Review Voucher (PRV) Program
---Implementation of Medical Countermeasures Innovation Act
---H.R. 3358/S.1771: Departments of Labor, HHS, Education, and Related Agencies Appropriations Act for FY 2018
---Pandemic and All-Hazards Preparedness Act (PAHPA) Reauthorization Act of 2017 (Reps. Brooks/Eshoo Discussion Draft)
Funding for Biodefense/Biomedical/Emergency Preparedness Research, Development and Procurement
---H.R. 3358/S.1771: Departments of Labor, HHS, Education, and Related Agencies Appropriations Act for FY 2018
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Health & Human Services - Dept of (HHS), Natl Security Council (NSC)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Hayley |
Alexander |
|
|
|
Jamie |
Gregorian |
|
|
|
Jeanne |
Haggerty |
|
|
|
Jordan |
Bartolomeo |
|
|
|
Phi D. |
Vu |
|
|
|
Phyllis |
Arthur |
|
|
|
Sarah |
Kyle |
|
|
|
Taylor |
Booth |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MED
16. Specific lobbying issues
Biodefense Research, Development and Procurement Issues (Non-funding)
---Tropical Disease Priority Review Voucher (PRV) Program
---Implementation of Medical Countermeasures Innovation Act
---H.R. 3358/S.1771: Departments of Labor, HHS, Education, and Related Agencies Appropriations Act for FY 2018
---Pandemic and All-Hazards Preparedness Act (PAHPA) Reauthorization Act of 2017 (Reps. Brooks/Eshoo Discussion Draft)
Funding for Antimicrobial Resistance Programs
---H.R. 3268/S.1603: Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2018
---H.R. 3358/S.1771: Departments of Labor, HHS, Education, and Related Agencies Appropriations Act for FY 2018
Funding for Biodefense/Biomedical/Emergency Preparedness Research, Development and Procurement
---H.R. 3358/S.1771: Departments of Labor, HHS, Education, and Related Agencies Appropriations Act for FY 2018
Funding for National Institutes of Health
---H.R. 3358/S.1771: Departments of Labor, HHS, Education, and Related Agencies Appropriations Act for FY 2018
Funding for the Centers for Disease Control and Prevention Vaccine Programs
---H.R. 3358/S.1771: Departments of Labor, HHS, Education, and Related Agencies Appropriations Act for FY 2018
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Natl Institutes of Health (NIH), Natl Security Council (NSC)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Hayley |
Alexander |
|
|
|
Jamie |
Gregorian |
|
|
|
Jeanne |
Haggerty |
|
|
|
Jordan |
Bartolomeo |
|
|
|
Phi D. |
Vu |
|
|
|
Phyllis |
Arthur |
|
|
|
Sarah |
Kyle |
|
|
|
Taylor |
Booth |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MMM
16. Specific lobbying issues
Medicaid
---Drug Benefit Design
---Pricing and Rebates
---Average Manufacturer Price Calculation
Reimbursement for Innovative Products
---Medicare Part B Physician-Administered Products
---Medicare Part D Prescription Drug Program
---S. 771: Improving Access to Affordable Prescription Drugs
---Third Party Support of Patient Premiums and Cost-Sharing Obligations
---S. 1688: Empowering Medicare Seniors to Negotiate Drug Prices Act of 2017
---Value-based Contracting and Communications
---CMS Hospital Inpatient Proposed Rule
---H.R. 242: Medicare Prescription Drug Price Negotiation Act
---H.R. 4138: Medicare Drug Price Negotiation Act
---H.R. 1892: Bipartisan Budget Act of 2018
---H.R. 1625: Consolidated Appropriations for FY 2018
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Office of Management & Budget (OMB)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Jeanne |
Haggerty |
|
|
|
Taylor |
Booth |
|
|
|
Jordan |
Bartolomeo |
|
|
|
Sarah |
Kyle |
|
|
|
John |
Murphy |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code SMB
16. Specific lobbying issues
Legislative Amendments to SEC Rule 12b-2 Filing Status Definitions
---H.R. 10: Financial Choice Act
Proxy Advisory Services
---Impact of Policies on Small Public Companies
---H.R. 4015: Corporate Governance Reform and Transparency Act of 2017
---H.R. 10: Financial Choice Act
Sarbanes Oxley Section 404 (b)
---H.R. 1645/S. 2126: Fostering Innovation Act
Short Selling Transparency
Small Business Intellectual Property Training
---H.R. 2655: Small Business Innovation Protection Act
XBRL Exemption for Small Public Companies
---H.R. 5054: Small Company Disclosure Simplification Act
---H.R. 10: Financial Choice Act
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Securities & Exchange Commission (SEC)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Charles |
Crain |
|
|
|
David |
Lachmann |
|
|
|
Jeanne |
Haggerty |
|
|
|
Cartier |
Esham |
|
|
|
Cameron |
Arterton |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code TAX
16. Specific lobbying issues
Biofuels (Non-Funding)
---Accelerated Depreciation of Biofuels Facilities Extension
---Production Tax Credit Extension
---H.R. 4118/S. 2005: Master Limited Partnership Parity Act
---H.R. 1892: Bipartisan Budget Act of 2018
Capital Formation Investment Incentives
---An Act to Modify Net Operating Loss Carryforwards (House Discussion Draft)
---H.R. 2297: PARTNER Act
---Reform of Capital Gains Rules
---Reform of Net Operating Loss Rules
---Reform of Passive Loss Rules
Corporate Tax Reform
Orphan Drug Issues
---Tax Credit
---Technical Amendments
Renewable Chemicals/Bio-based Products (Non-Funding)
---Expansion of Master Limited Partnerships to Renewable Chemicals
---Investment Tax Credit
---Production Tax Credit
---HR 3149/S. 1980: Renewable Chemicals Act of 2017
---H.R. 4118/S. 2005: Master Limited Partnership Parity Act
Research & Development Tax Credit Reforms
---Refundable R&D Credit
Vaccines and Infectious Diseases
---Vaccine Injury Compensation Program
---H.R. 4993: Vaccine Access Improvement Act
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Charles |
Crain |
|
|
|
Charles |
Fritts |
|
|
|
Erick |
Lutt |
|
|
|
Jeanne |
Haggerty |
|
|
|
Rina |
Singh |
|
|
|
Cartier |
Esham |
|
|
|
Cameron |
Arteron |
|
|
|
Taylor |
Booth |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code TRD
16. Specific lobbying issues
Drug Importation
---H.R. 3268/S.1603: Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2018
---H.R. 3358/S.1771: Departments of Labor, HHS, Education, and Related Agencies Appropriations Act for FY 2018
---S. 771: Improving Access to Affordable Prescription Drugs
---S.469: Affordable and Safe Prescription Drug Importation Act
Foreign Agricultural Biotechnology Laws and Regulations
---Asynchronous Approvals
---China Biotechnology Regulations
---EU Ag-Biotech Policies and Regulations
---Like-minded Countries Initiatives
Foreign Drug Data Protection Laws
Funding for the USDA
---H.R. 3268/S.1603: Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2018
---Foreign Agriculture Service Funding and Authority
------H.R. 5379: Growing American Food Exports Act
Intellectual Property International Enforcement
---Compulsory Licensing
---World Trade Organization - Special 301 Submission
---India
---Canada
---Malaysia
International IP Patent Law Harmonization
North American Free Trade Agreement (NAFTA) Renegotiation
---Ag-Biotech Provisions
---IP Provisions
---Pricing and Reimbursement Provisions
Trade and Foreign Drug Price Controls
UN High Level Commission on Access to Medicines
---IP Proposals
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Agriculture - Dept of (USDA), White House Office, U.S. Trade Representative (USTR)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Charles |
Fritts |
|
|
|
David |
Lachmann |
|
|
|
Jamie |
Gregorian |
|
|
|
Jeanne |
Haggerty |
|
|
|
Jordan |
Bartolomeo |
|
|
|
Joseph |
Damond |
|
|
|
Matthew |
OMara |
|
|
|
Hans |
Sauer |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Information Update Page - Complete ONLY where registration information has changed.
20. Client new address
| Address |
|
||||||
| City |
|
State |
|
Zip Code |
|
Country |
|
21. Client new principal place of business (if different than line 20)
| City |
|
State |
|
Zip Code |
|
Country |
|
22. New General description of client’s business or activities
LOBBYIST UPDATE
23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client
|
|
||||||||
| 1 |
|
3 |
|
||||||
| 2 |
|
4 |
|
ISSUE UPDATE
24. General lobbying issue that no longer pertains
|
|
|
|
|
|
|
|
|
AFFILIATED ORGANIZATIONS
25. Add the following affiliated organization(s)
Internet Address:
| Name | Address |
Principal Place of Business (city and state or country) |
||||||||||||
| ||||||||||||||
|
||||||||||||||
26. Name of each previously reported organization that is no longer affiliated with the registrant or client
| 1 | 2 | 3 |
FOREIGN ENTITIES
27. Add the following foreign entities:
| Name | Address |
Principal place of business (city and state or country) |
Amount of contribution for lobbying activities | Ownership percentage in client | ||||||||||
| ||||||||||||||
|
% | |||||||||||||
28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization
| 1 | 3 | 5 |
| 2 | 4 | 6 |